VivoSeq
Psychiatry

Conduct Disorder

5

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Conduct Disorder is an early-stage landscape with 5 programs across 3 companies. The most active players are Takeda, Solvay Pharmaceuticals, Johnson & Johnson. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 1S

Solvay Pharmaceuticals

2 programs

ApprovedJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed3 · 100%

Clinical Trials

Trial Activity

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00250354·110 enrolled
A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00266552·118 enrolled
Long-Term Lithium Treatment for Aggressive Conduct Disorder
Completed·—·Phase 3·NCT00000385·59 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)